Phil Taylor, Author at

Genomic testing ‘should be offered to all cancer patients in Scotland’

Phil Taylor AstraZeneca, Eli Lilly, genomics, NHS, Novartis, Oncology, patients, precision medicine, Roche, Scotland 0 Comment

A group representing pharma companies selling precision therapies for cancer has called for a change to the way

Genomic testing ‘should be offered to all cancer patients in Scotland’

https://pharmaphorum.com/news/genomic-testing-should-be-offered-to-all-cancer-patients-in-scotland/

News/ News/ Sales and Marketing

Grünenthal buys into Kyowa Kirin’s mature medicines portfolio

Phil Taylor Grunenthal, Kyowa Kirin, M&A, pain, Sales and Marketing 0 Comment

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan’s Kyowa

Grünenthal buys into Kyowa Kirin’s mature medicines portfolio

https://pharmaphorum.com/news/grunenthal-buys-into-kyowa-kirins-mature-medicines-portfolio/

Helsinki_University _Hospital_cancer_care

Digital/ News/ News/ News/ Oncology

EU launches AI-powered real-world data project for cancer therapies

Phil Taylor digital, digital health, EU, Health Technology Assessment, HEOR, Horizon Europe programme, Oncology 0 Comment

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims

EU launches AI-powered real-world data project for cancer therapies

https://pharmaphorum.com/news/eu-launches-ai-powered-real-world-data-project-for-cancer-therapies/

News/ News/ R&D

mRNA can deliver universal flu vaccine, say US researchers

Phil Taylor infectious disease, influenza, mRNA, mRNA vaccines, vaccines 0 Comment

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of

mRNA can deliver universal flu vaccine, say US researchers

https://pharmaphorum.com/news/mrna-can-deliver-universal-flu-vaccine-say-us-researchers/

Market Access/ News/ News/ News/ Oncology

FDA rejects Spectrum’s lung cancer drug poziotinib

Phil Taylor Non-small cell lung cancer, Oncology, poziotinib, regulatory, Spectrum Pharmaceuticals 0 Comment

The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor

FDA rejects Spectrum’s lung cancer drug poziotinib

https://pharmaphorum.com/news/fda-rejects-spectrums-lung-cancer-drug-poziotinib/

News/ News/ Oncology

Pharma M&A rumour mill grinds out Mirati’s name again

Phil Taylor Amgen, KRAS, Lumakras, M&A, Merck & Co, Mirati 0 Comment

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for

Pharma M&A rumour mill grinds out Mirati’s name again

https://pharmaphorum.com/news/pharmas-ma-rumour-mill-grinds-out-miratis-name-again/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Opdivo backed by NICE for rare gastro-oesophageal cancers

Phil Taylor Bristol-Myers Squibb, gastric cancer, HEOR, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo 0 Comment

Bristol-Myers Squibb’s Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal

Opdivo backed by NICE for rare gastro-oesophageal cancers

https://pharmaphorum.com/news/opdivo-backed-by-nice-for-rare-gastro-oesophageal-cancers/

Digital/ News/ News

EMA unveils first projects as data partners join DARWIN EU project

Phil Taylor big data, DARWIN, digital, digital health, ema, EU, real world data, Real World Evidence 0 Comment

Two years ago, the EMA proposed a set of recommendations to unlock the potential of big data for

EMA unveils first projects as data partners join DARWIN EU project

https://pharmaphorum.com/news/ema-unveils-first-projects-as-data-partners-join-darwin-eu-project/

News/ News/ News/ R&D/ Sales and Marketing

J&J builds case for antidepressant Spravato with head-to-head trial

Phil Taylor depression, Janssen, Johnson & Johnson, Psychiatry, Spravato 0 Comment

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in

J&J builds case for antidepressant Spravato with head-to-head trial

https://pharmaphorum.com/news/jj-builds-case-for-antidepressant-spravato-with-head-to-head-trial/

Trending

About Phil Taylor

Posts by Phil Taylor:

Genomic testing ‘should be offered to all cancer patients in Scotland’

Grünenthal buys into Kyowa Kirin’s mature medicines portfolio

EU launches AI-powered real-world data project for cancer therapies

mRNA can deliver universal flu vaccine, say US researchers

FDA rejects Spectrum’s lung cancer drug poziotinib

Pharma M&A rumour mill grinds out Mirati’s name again

Opdivo backed by NICE for rare gastro-oesophageal cancers

EMA unveils first projects as data partners join DARWIN EU project

J&J builds case for antidepressant Spravato with head-to-head trial

Trending

About Phil Taylor

Posts by Phil Taylor:

Login